Fu's subcutaneous needling for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests an acupuncture-like treatment called Fu's subcutaneous needling to see if it can help improve vision in people with the dry form of age-related macular degeneration (AMD), a common cause of vision loss in older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old
- You have been diagnosed with dry age-related macular degeneration (AMD), not the wet form
- You have not had eye surgery in the past 6 months
- You do not have other serious eye conditions like acute glaucoma or mature cataracts
- You are not pregnant or breastfeeding
- You have not taken certain medications or foods that affect eye blood flow in the last week (like caffeine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a traditional Chinese medicine pill, Sanhuang Jingshiming, can help people with wet age-related macular degeneration (a condition where abnormal blood vessels leak fluid in the eye). It aims to see if the pill improves vision and is safe compared to standard treatment.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
Hear when a new Age - Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.